ARCT compared with NTLA: revenue, margins and what each company keeps, and the suppliers and customers both name

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

NTLAIntellia Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ARCTArcturus Therapeutics Holdings Inc.

NTLAIntellia Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ARCT 3

—Biomedical Advanced Research and Development Authority (BARDA)unlistedcustomer

—CSL Seqirusunlistedcustomer

—Meiji Seika Pharmaunlistedcustomer

Shared 0

No shared counterparties.

Only NTLA 4

REGNRegeneron Pharmaceuticalscustomer

CRBUCaribou Biosciencessupplier

—AvenCell Therapeuticsunlistedcustomer

—SparingVision SAS

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlistedcustomer

ARCTArcturus Therapeutics Holdings Inc.

9.37▼−13.76%· post 9.37

Mkt cap$309.0MRevenue$18MQ3 FY26Revenue$82MFY25

NTLAIntellia Therapeutics, Inc.

11.08▼−9.99%· post 11.15

ClosedNov 5 '26

Mkt cap$1.7BRevenue$7MQ3 FY26Revenue$68MFY25

Compare

ClosedNov 5 '26

ARCTArcturus Therapeutics Holdings Inc.

NTLAIntellia Therapeutics, Inc.

9.37▼−13.76%post 9.37

Price

11.08▼−9.99%post 11.15

$309.0M

Mkt cap

$1.7B

Q3 FY26$18M

Revenue

$7MQ3 FY26

FY25$82M

Revenue

$68MFY25

ARCT9.37▼−13.76%vsNTLA11.08▼−9.99%ClosedNov 5 '26